SPDR Series Trust has recently filed a summary prospectus for its State Street SPDR US Small Cap Low Volatility Index ETF (ticker: SMLV). This filing is significant as it underscores the fund's aim to provide investors with a low-volatility investment option, appealing to those looking for stability in their portfolios.
The filing, dated October 30, 2026, details the fund's investment objectives, fees, and associated risks. With the ETF market growing increasingly competitive, SPDR Series Trust is positioning itself as a key player in offering low-volatility investment strategies.
Background
SPDR Series Trust, incorporated in Massachusetts, operates as an investment entity. The company has undergone several name changes, previously known as StreetTracks Series Trust and Index Exchange Listed Securities Trust. The current filing is part of a series of recent filings, all dated October 30, 2026, which include multiple 497K forms.
What the Filing Says
The summary prospectus outlines the investment objective of the State Street SPDR US Small Cap Low Volatility Index ETF. It seeks to provide investment results that correspond generally to the total return performance of a small cap, low volatility index. The prospectus emphasizes the importance of reviewing the fund's prospectus and statement of additional information before investing.
Impact
This filing may affect a range of investors looking for low-volatility options in their portfolios. The fund's management fees are set at 0.12%, which is relatively competitive in the ETF market. The filing also highlights the fund's strategy of investing at least 80% of its net assets in securities comprising the index it seeks to track, which may appeal to conservative investors.
What's Next
The filing does not specify what happens next, but it is likely that SPDR Series Trust will continue to monitor market conditions and investor interest as it promotes its new ETF.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






